Citing Heart Problems, FDA Calls For Limiting Use Of Antimalarial Drugs Trump Championed

A Salvadoran Health Ministry worker shows a package of bottles of HydroxyChloroquine pills to be distributed in hospitals in San Salvador on April 21, 2020, amid the COVID-19 coronavirus outbreak. (Photo by Yuri CORT... A Salvadoran Health Ministry worker shows a package of bottles of HydroxyChloroquine pills to be distributed in hospitals in San Salvador on April 21, 2020, amid the COVID-19 coronavirus outbreak. (Photo by Yuri CORTEZ / AFP) (Photo by YURI CORTEZ/AFP via Getty Images) MORE LESS

The Food and Drug Administration on Friday warned that heart complications caused by the antimalarial medications championed by President Donald Trump “can be life-threatening.”

The FDA flagged “reports of serious heart rhythm problems” in COVID-19 patients treated with the antimalarials Trump has hyped, hydroxychloroquine or chloroquine. It also pointed out the “increased use of these medicines through outpatient prescriptions.”

“Therefore, we would like to remind health care professionals and patients of the known risks associated with both hydroxychloroquine and chloroquine,” the agency said, warning against using the drugs outside of a clinical or hospital setting.

Trump has for weeks boosted the drugs despite the lack of widespread evidence that they are effective against COVID-19.

A study of VA hospital patients recently failed to find hydroxychloroquine effective against the disease, and a Brazilian study of chloroquine use on COVID-19 patients was halted due to the risk of fatal heart rate irregularities like those described in the FDA warning.

Just last month the FDA issued an emergency use authorization, or EUA, to allow millions of donated doses of chloroquine and hydroxychloroquine to be distributed to hospitals through state public health officials. The director of the agency that received the authorization, who was recently demoted to another role, alleged this week that he faced political pressure to allow the widespread use of the drug.

At the time the EUA was issued, in late March, medical and regulatory experts rang alarm bells about insufficient evidence supporting the drugs.

“I would like to see who [at the FDA’s Medical Countermeasures Initiative] signed off on this EUA despite the total lack of scientific evidence that chloroquine/hydroxychloroquine are beneficial in the treatment of COVID-19,” Luciana Borio, the FDA’s former acting top scientist, wrote in response to the emergency authorization.

“EUA is supposed to be issued when the evidence indicates that benefits outweigh the risks.”

Trump’s boosterism of the drugs has prompted fear among regular users — the medicines were used to treat lupus and rheumatoid arthritis long before the COVID-19 pandemic — about supply issues. The heart complications among COVID-19 patients using the antimalarials have arisen more recently as the drugs have come under increased scrutiny.

“We are continuing to investigate these safety risks in patients with COVID-19 and will communicate publicly when more information is available,” the FDA wrote.

Dear Reader,

When we asked recently what makes TPM different from other outlets, readers cited factors like honesty, curiosity, transparency, and our vibrant community. They also pointed to our ability to report on important stories and trends long before they are picked up by mainstream outlets; our ability to contextualize information within the arc of history; and our focus on the real-world consequences of the news.

Our unique approach to reporting and presenting the news, however, wouldn’t be possible without our readers’ support. That’s not just marketing speak, it’s true: our work would literally not be possible without readers deciding to become members. Not only does member support account for more than 80% of TPM’s revenue, our members have helped us build an engaged and informed community. Many of our best stories were born from reader tips and valuable member feedback.

We do what other news outlets can’t or won’t do because our members’ support gives us real independence.

If you enjoy reading TPM and value what we do, become a member today.

Latest News
Masthead Masthead
Founder & Editor-in-Chief:
Executive Editor:
Managing Editor:
Associate Editor:
Investigations Desk:
Director of Audience:
Editor at Large:
General Counsel:
Head of Product:
Director of Technology:
Associate Publisher:
Front End Developer:
Senior Designer: